Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label natalizumab safety study in relapsing multiple sclerosis after STRATA
2014-003669-97Phase 4Completed
- Sponsor
- Biogen
- Start
- Sep 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of natalizumab in multiple sclerosis (MS), sponsored by Biogen. Primary endpoint: Incidence of adverse events and serious adverse events. Started Sep 2014; status: completed.
02
Drugs
natalizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2014-003669-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003669-97.